(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual revenue growth rate of 14.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.3%.
Vanda Pharmaceuticals's revenue in 2024 is $182,022,000.On average, 2 Wall Street analysts forecast VNDA's revenue for 2024 to be $11,361,849,375, with the lowest VNDA revenue forecast at $11,188,145,748, and the highest VNDA revenue forecast at $11,535,553,003. On average, 2 Wall Street analysts forecast VNDA's revenue for 2025 to be $13,581,525,264, with the lowest VNDA revenue forecast at $13,406,655,840, and the highest VNDA revenue forecast at $13,756,394,688.
In 2026, VNDA is forecast to generate $15,965,578,411 in revenue, with the lowest revenue forecast at $15,965,578,411 and the highest revenue forecast at $15,965,578,411.